Trium Capital LLP Buys New Holdings in HilleVax, Inc. (NASDAQ:HLVX)

Trium Capital LLP bought a new position in HilleVax, Inc. (NASDAQ:HLVX - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 378,205 shares of the company's stock, valued at approximately $548,000. Trium Capital LLP owned 0.75% of HilleVax at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Intech Investment Management LLC acquired a new position in HilleVax during the 4th quarter worth approximately $26,000. Bank of Montreal Can boosted its stake in shares of HilleVax by 47.1% during the 4th quarter. Bank of Montreal Can now owns 35,763 shares of the company's stock worth $74,000 after buying an additional 11,459 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of HilleVax by 328.0% during the 4th quarter. Russell Investments Group Ltd. now owns 38,236 shares of the company's stock worth $79,000 after buying an additional 29,303 shares during the last quarter. Two Sigma Advisers LP boosted its stake in shares of HilleVax by 76.8% during the 4th quarter. Two Sigma Advisers LP now owns 41,200 shares of the company's stock worth $85,000 after buying an additional 17,900 shares during the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new position in shares of HilleVax during the 4th quarter worth about $89,000. 86.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright restated a "neutral" rating and set a $2.00 price objective on shares of HilleVax in a research note on Monday, March 31st.

HilleVax Stock Down 0.9%

Shares of NASDAQ HLVX traded down $0.02 during trading hours on Thursday, hitting $2.10. The company had a trading volume of 88,297 shares, compared to its average volume of 326,018. The stock has a market capitalization of $105.29 million, a P/E ratio of -0.98 and a beta of 0.76. HilleVax, Inc. has a 1-year low of $1.34 and a 1-year high of $2.15. The firm's 50 day moving average is $1.94 and its 200-day moving average is $1.85.

HilleVax (NASDAQ:HLVX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.25. On average, sell-side analysts predict that HilleVax, Inc. will post -2.64 earnings per share for the current year.

HilleVax Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.